5,694 results match your criteria: "Hairy Cell Leukemia"
Pure Biclonal Hairy Cell Leukemia-Apt Diagnosis with Multicolor Flow Cytometry.
Int J Hematol Oncol Stem Cell Res
October 2024
Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.
Hairy cell leukemia (HCL) is a rare B-cell neoplasm that constitutes around 2 percent of all lymphoid leukemias and occurs more frequently in elderly males. The usual triad of HCL includes pancytopenia, splenomegaly, and hairy cells in the bone marrow. This is a case of an atypical presentation of biclonal HCL diagnosed on flow cytometry; the existence of biclonal HCL is extremely rare with very few case reports.
View Article and Find Full Text PDFHairy-Cell Leukemia. Reply.
N Engl J Med
December 2024
University and Hospital of Perugia, Perugia, Italy.
The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease.
Leuk Lymphoma
December 2024
Hematology CHU Caen Normandie, INSERM1245, MICAH, Normandie University of Caen and Rouen, UNIROUEN, UNICAEN, Hematology Institute, University Hospital Caen, Caen, France.
Hairy cell leukemia (HCL) is an indolent malignancy of mature B-lymphocytes. While existing front-line therapies achieve excellent initial results, a significant number of patients relapse and become increasingly treatment resistant. A major molecular driver of HCL is aberrant interlocking expression of the transcription factor JunD and the intracellular signaling molecule RhoH.
View Article and Find Full Text PDFElectrochemical quantification based on the interactions of nucleoside analog cladribine with dsDNA via experimental and in-silico studies.
Int J Biol Macromol
January 2025
Department of Chemistry, Faculty of Science and Letters, Istanbul Technical University, Maslak, Istanbul 34469, Türkiye. Electronic address:
Article Synopsis
Cell therapy for a rare disease- hairy cell leukemia variant.
Oncoimmunology
December 2024
Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Hairy cell leukemia variant (HCL-v) is a rare malignancy of clonal mature B-cells that follows a chronic disease course. HCL-v patients are often resistant to purine nucleoside analogs, which are the first-line therapy. To address the shortcomings of current therapy for HCL-v, we investigated the activity of a BAFF ligand-based CAR-T cell which binds to all three BAFF receptors, BAFF-receptor, TACI, and BCMA.
View Article and Find Full Text PDFVenous thromboembolism in patients with hairy cell leukemia.
Hematology
December 2024
Guthrie Robert Packer Hospital, Sayre, PA, USA.
Article Synopsis
A monstrous relapsed hairy cell leukaemia with large cells.
Br J Haematol
November 2024
Department of Biological Hematology, Centre Hospitalier Universitaire de Caen, Caen, France.
Concurrent Zoster Sine Herpete and Hepatosplenic Fungal Infection in a Cancer Patient: A Case Report.
Cureus
October 2024
Infectious Diseases and Tropical Medicine, Moffitt Cancer Center, Tampa, USA.
Article Synopsis
Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions.
Expert Rev Hematol
December 2024
CHU Caen Normandie, Avenue Côte de Nacre, Hématologie, Caen cedex, France.
Article Synopsis
- * Differentiating HCL from similar disorders is crucial, as recent advancements in molecular biology and new drug developments (like BRAF and MEK inhibitors) show promise for relapsed cases, alongside ongoing clinical trials.
- * For treating fit patients with HCL or its variant, the combination of Cladribine and rituximab is standard, while BRAF and BTK inhibitors are considered for patients with relapsed conditions; optimal treatment strategies are still being explored. *
Hairy Cell Leukemia Following Acute Myeloid Leukemia, Concomitant or Secondary?
Arch Iran Med
November 2024
Department of Clinical Laboratory, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai, China.
A 62-year-old man diagnosed with acute myeloid leukemia (AML) showed limited responses to two courses of azacitidine (AZA)+Venetoclax (VEN) therapy. Twenty days after being transferred to our hospital, flow cytometry with broad antigen coverage and mutation analysis confirmed the presence of a second malignancy, hairy cell leukemia (HCL). Following haploidentical combined umbilical cord blood transplantation, the patient achieved complete remission (CR) for both AML and HCL.
View Article and Find Full Text PDFExpert consensus on the diagnosis and treatment of solid tumors with BRAF mutations.
Innovation (Camb)
November 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing 100142, P.R. China.
Article Synopsis
- * BRAF mutations are common in various cancers, and targeted therapies, especially BRAF inhibitors like dabrafenib and trametinib, are developed for treating solid tumors with these mutations.
- * An expert consensus has been established to improve the diagnosis and treatment of solid tumors with BRAF mutations, focusing on summarizing their clinical features, recommending genetic testing methods, and creating a systematic approach for patient care.
Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types.
PLoS One
November 2024
Hematogenix, Chicago, Illinois, United States of America.
Article Synopsis
- * The study analyzed 292 tumor samples and found that ROR1 was highly prevalent in chronic lymphocytic leukemia and hairy cell leukemia, while its expression was more varied in other cancers like mantle cell lymphoma and triple negative breast cancer.
- * The research highlights the need for tailored patient selection strategies due to the diverse expression of ROR1 across various hematological malignancies and solid tumors, which could influence therapeutic development.
Concurrent involvement of the bone marrow by BRAF V600E-mutant melanoma and hairy cell leukemia.
J Hematop
December 2024
Department of Pathology and Laboratory Medicine, University of Virginia, Charlottesville, VA, USA.
Closing the gap between biology and classification in splenic B-cell lymphomas.
Histopathology
January 2025
Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Article Synopsis
Hairy-Cell Leukemia.
N Engl J Med
October 2024
From the Institute of Hematology and the Center for Hemato-Oncology Research, Department of Medicine and Surgery, University and Hospital of Perugia, Perugia, Italy.
Rare Clinical Symptoms in Hairy Cell Leukemia: An Overview.
Cancers (Basel)
September 2024
Department of Dermatology, Medical University of Lodz, 90-647 Lodz, Poland.
Article Synopsis
- Hairy cell leukemia (HCL) is a rare type of B-cell cancer, often asymptomatic and typically found during routine blood tests, though some patients may show symptoms like low blood cell counts and enlarged spleen.
- This review analyzed literature from various databases regarding unusual clinical symptoms linked to HCL, including skin, bone, neurological, and pulmonary issues.
- While it's uncommon, HCL can affect multiple organs beyond the bones and bloodstream, with documented cases of involvement in areas like the skin, central nervous system, and heart.
Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions.
Br J Haematol
December 2024
Section of Pathology, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Article Synopsis
Non-canonical variants and rearrangements in hairy cell leukemia.
Oncol Res
September 2024
Cancer Molecular Diagnostics, St. James's Hospital, Dublin, D08 W9RT, Ireland.
Article Synopsis
- * Most HCL patients have the V600E mutation, making it a key target for treating those who don't respond to standard therapies, but some may have different mutations.
- * Diagnosing HCL patients without the V600E mutation requires careful evaluation for other genetic changes, which could reveal new insights into the disease and improve targeted treatment options.
Hairy cell leukemia with an atypical extranodal presentation: A clinicopathological analysis of four cases.
Hum Pathol
October 2024
Hematopathology Unit, Hospital Clínic, University of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.